Clinical Trials
17 trialsNCT02783625 2026-04-24
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT06963346 2026-03-09
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Suspended
NCT02512172 2025-12-03
A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02512497 2025-09-19
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
NCT02616965 2025-04-04
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
Fox Chase Cancer Center
Phase 1 Completed
NCT04774068 2025-01-17
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01302808 2021-01-20
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase 1 Completed
NCT02181218 2020-11-17
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Washington University School of Medicine
Phase 1 Completed
NCT04233697 2020-08-13
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
Columbia University
Phase 1 Withdrawn
NCT01902225 2020-06-09
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
University of California, San Francisco
Phase 1 Completed
NCT01742793 2020-03-04
RID
Yale University
Phase 1 Terminated
NCT01738594 2019-08-29
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Northwestern University
Phase 1 Terminated
NCT02061449 2018-12-24
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
NYU Langone Health
Phase 1 Terminated
NCT01590732 2018-09-19
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00963274 2018-04-23
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Virginia Commonwealth University
Phase 1 Completed
NCT01537744 2017-03-24
A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed